Almac and the Royal Society of Chemistry host a workshop on the use of analytical techniques to control and monitor solid form
November 19, 2010
Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.
The milestone event, attended by representatives from industry and academia, included presentations and round table discussion regarding x-ray powder diffraction, hyper differential scanning calorimetry and Raman spectroscopy.
An important element of the workshop was the presentation of results from Almac’s collaborative research with Queens University Belfast regarding Raman spectroscopy. “The effect of crystal orientation on Raman Spectra” has been observed for the first time and these findings will have profound implications for the use of this technique in characterising physical forms.
Linda McCausland, Head of Physical Sciences, Almac, commented: “Almac has invested extensively in research and development in the field of solid state science and are currently involved in a number of academic collaborations. The research output of these studies will be available to clients to augment the development of their drugs. This workshop provided an opportunity for Almac to share its expertise with the pharmaceutical community and we are very proud to have worked with the Royal Society of Chemistry in staging such an exciting event.”
She added; “We do feel that the insight from the study’s findings are testimony to Almac’s status as a leader in the field of solid state science.”
Prof Duncan Burns, Analytical Division, Royal Society of Chemistry, remarked: “The workshop was a truly memorable day of excellent and well presented analytical science”.
De Facto Communications
Tel: + 44 207 8613019
Notes to Editors:
The Almac Group offers a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs almost 3,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has officially gained full possession of its new $120m North American Headquarters which started in July 2008 and employees will relocate during the fall.
For more information on Almac, please visit www.almacgroup.com